Domov › Akútna biphenotypová leukémia › Wisconsin
Klinické štúdie Akútna biphenotypová leukémia v štáte Wisconsin
5 štúdií pre Akútna biphenotypová leukémia hľadá účastníkov v zariadeniach v štáte Wisconsin.
Mestá v štáte Wisconsin
Oficiálny text štúdie (anglicky)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Children's Hospital of Wisconsin, Milwaukee
Prebieha náborFáza 2
365 Days · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06317662Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Marshfield Medical Center-Marshfield, Marshfield
- a 1 ďalších
Prebieha náborFáza 3
365 Days – 25 Years · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Marshfield Medical Center-Marshfield, Marshfield
Prebieha náborFáza 1/2
Do veku 22 · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT04726241MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
- Children's Wisconsin, Milwaukee
Prebieha nábor
Vek 0 až 25 · Všetky pohlavia · Aktualizované 13. 5. 2026 · NCT05794880Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital of Wisconsin, Milwaukee
Prebieha náborFáza 1
Vek 1 až 21 · Všetky pohlavia · Aktualizované 6. 12. 2024 · NCT05476770Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.